Biogen Inc. BIIB
We take great care to ensure that the data presented and summarized in this overview for BIOGEN INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BIIB
View all-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.49 Billion0.06% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$2.44 Billion2.37% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.17 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.34MShares$1.1 Billion0.06% of portfolio
-
Wellington Management Group LLP Boston, MA5.13MShares$766 Million0.18% of portfolio
-
Jpmorgan Chase & CO New York, NY5.1MShares$762 Million0.08% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.26MShares$636 Million0.5% of portfolio
-
Geode Capital Management, LLC Boston, MA3.61MShares$540 Million0.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.91MShares$286 Million0.04% of portfolio
-
Morgan Stanley New York, NY1.89MShares$282 Million0.03% of portfolio
Latest Institutional Activity in BIIB
Top Purchases
Top Sells
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at BIIB
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 09
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
110
-1.99%
|
$17,270
$157.21 P/Share
|
Dec 06
2024
|
Robin Kramer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
170
-2.58%
|
$26,690
$157.78 P/Share
|
Dec 06
2024
|
Robin Kramer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
351
+5.07%
|
-
|
Dec 06
2024
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
206
-3.59%
|
$32,342
$157.78 P/Share
|
Dec 06
2024
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
426
+6.91%
|
-
|
Nov 05
2024
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Bona fide gift
|
Indirect |
20,082
+50.0%
|
-
|
Nov 05
2024
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Bona fide gift
|
Direct |
20,082
-38.86%
|
-
|
Nov 01
2024
|
Jane Grogan Head of Research |
SELL
Payment of exercise price or tax liability
|
Direct |
204
-29.35%
|
$35,292
$173.79 P/Share
|
Nov 01
2024
|
Jane Grogan Head of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
695
+50.0%
|
-
|
Sep 03
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
431
-7.5%
|
$87,924
$204.22 P/Share
|
Aug 30
2024
|
Priya Singhal Head of Development |
SELL
Payment of exercise price or tax liability
|
Direct |
807
-12.31%
|
$164,628
$204.76 P/Share
|
Aug 30
2024
|
Priya Singhal Head of Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,668
+20.29%
|
-
|
Jun 21
2024
|
Jesus B Mantas Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+15.35%
|
-
|
Jun 21
2024
|
Stephen A Sherwin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+6.26%
|
-
|
Jun 21
2024
|
Monish D Patolawala Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+50.0%
|
-
|
Jun 21
2024
|
Susan Langer Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+32.69%
|
-
|
Jun 21
2024
|
Eric K Rowinsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+5.75%
|
-
|
Jun 21
2024
|
Maria C Freire Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+23.16%
|
-
|
Jun 21
2024
|
William A Hawkins Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+17.11%
|
-
|
Jun 21
2024
|
Caroline Dorsa Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,785
+6.29%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 11.2K shares |
---|---|
Exercise of conversion of derivative security | 53.4K shares |
Open market or private purchase | 455 shares |
Bona fide gift | 20.1K shares |
Payment of exercise price or tax liability | 21.2K shares |
---|---|
Bona fide gift | 20.1K shares |
Open market or private sale | 2.06K shares |